Fondazione Biotecnopolo di Siena
  • ITA
  • ENG
Cerca nel sito FBS
  • Home
  • Foundation
    • Governance
  • CNAP
  • Open Governance
  • Tenders
  • Work with us
  • News
  • Contacts
  • Home
  • Foundation
    • Governance
  • CNAP
  • Open Governance
  • Tenders
  • Work with Us
  • News
  • Contacts
  • ITA
  • ENG
  • Home
  • Foundation
    • Governance
  • CNAP
  • Open Governance
  • Tenders
  • Work with Us
  • News
  • Contacts
  • ITA
  • ENG

Home > News

Building a Stronger and Smarter Europe

Rino Rappuoli

Professor Rino Rappuoli, Scientific Director of the Biotecnopolo di Siena Foundation, shares his views in an interview for the official newsletter of HERA – the European Health Emergency Preparedness and Response Authority.

He reflects on the strategic importance of creating an integrated European system for vaccine development and production. A system that can respond to global health challenges with speed, skill, and autonomy.

In the interview, Professor Rappuoli recalls how his scientific journey began in Siena, inspired by the Tuscan Serotherapy Institute (Sclavo). He then explains the vision behind the work of the Biotecnopolo Foundation: to build an ecosystem able to face new health threats before they turn into emergencies.

This vision relies on advanced public research, strong cooperation among countries, and active collaboration between the public and private sectors.

A key part of the conversation is the European Vaccine Hub (EVH). This pan-European infrastructure was created after the COVID-19 pandemic. It is built on four pillars: basic research, preclinical studies, clinical trials, and production/regulation. Its goal is to connect scientific excellence across Europe, reduce fragmentation, and promote collaboration.

The Biotecnopolo di Siena leads the first pillar – discovery. It focuses on identifying and developing monoclonal antibodies and vaccine candidates against high-risk viruses and bacteria.

Building stable relationships, shared infrastructures, and coordinated processes between universities, research centers, biotech companies, and regulatory bodies is essential. It is the only way to ensure fast and effective responses in times of crisis.

The EVH aims to support this network. It is open, inclusive, and accessible to startups, small research centers, and manufacturers who want to contribute to Europe’s vaccine development.

The message is clear: Europe has the skills, vision, and energy to lead in global health science and technology. But this will only be possible with adequate resources and strong political commitment.

CATEGORY

News

publication data

5 August 2025

TAG

Biotecnopolo, Research, rino rappuoli, scientific research, Vaccine

Back to news

DISCOVER MORE

Let’s keep in touch

DISCOVER MORE

Contatti
Let’s keep in touch
Fondazione Biotecnopolo di Siena

Fondazione Biotecnopolo di Siena
Strada del Petriccio e Belriguardo 35
53100 Siena - Italia

+39 0577 231411

Fiscal Code: 92078010524

Unique Code: JBZHXM

Regime IV: Split Payment
Pursuant to Article 17b,
paragraph 1, of Presidential Decree.
Oct. 26, 1972, no. 633

Home

Foundation

CNAP

Open Governance

Tenders

Work with us

News

Contacts

© 2024 FBS. All rights reserved.

Accessibility

Privacy & Cookies Policy

Terms and conditions

Fondazione Biotecnopolo di Siena
Strada del Petriccio e Belriguardo 35
53100 Siena - Italia

+39 0577 231411

Fiscal Code: 92078010524
Unique Code: JBZHXM

Regime IV: Split Payment Pursuant to Article 17b, paragraph 1, of Presidential Decree.
Oct. 26, 1972, no. 633

Home

Foundation

CNAP

Open Governance

Tenders

Work with us

News

Contacts

Accessibility

Privacy & Cookies Policy

Terms and conditions

© 2024 FBS All rights reserved.